Please ensure Javascript is enabled for purposes of website accessibility

Why Curis, Inc. Is Soaring Today

By Brian Feroldi – May 31, 2018 at 2:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Traders cheer after the company reports upbeat regulatory news. Here's what investors need to know.

What happened

Curis, Inc. (CRIS 2.86%), a beaten up clinical-stage biopharma focused on cancer, jumped 23% as of 2:43 p.m. EDT on Thursday in response to announcing that one of its key compounds has received Food and Drug Administration (FDA) Fast Track designation.

So what

Curis stated that the FDA bestowed Fast Track designation upon its lead compound fimepinostat, which is also known as CUDC-907, as a hopeful treatment for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The agency made this decision in response to data that the company had previously released showing that fimepinostat elicited a complete or partial response in about 25% of patients. 

Scientist looking at microscope cancer research

Image source: Getty Images.

Curis CEO Ali Fattaey was excited to share this news with investors:

We are pleased with this Fast Track designation, which will enable us to accelerate the development of fimepinostat for patients with R/R DLBCL, including patients whose tumors have MYC alterations. Patients with this disease have a very poor prognosis and we are encouraged by the FDA's recognition of the unmet need that may be addressed by fimepinostat, as well as the potential durable benefit that fimepinostat can provide for these patients.

CEO Fattaey also said that the company plans to enroll patients in a pivotal study later this year. 

Given the news, it isn't hard to figure out why traders are cheering today.

Now what

Investors haven't had a lot of positive news out of Curis lately, so today's update should serve as some reprieve. A few days ago, the company's Chief Medical Officer chose to retire and return to academia. Shortly after that, the company enacted a 1-for-5 reverse stock split in order to bring its share price above $1. That's never a good sign.

The company's financial situation doesn't exactly inspire optimism, either. Curis spent $10.7 million last quarter, which is a sizable number when compared to the $49 million on its balance sheet at quarter's end. There's also $40 million in debt obligations to consider.

With fimepinostat poised to enter pivotal trials soon, the company's cash burn almost certainly will rise from here. That means that another capital raise could be in the cards sometime soon, which isn't great news given the company's long track record of destroying shareholder value:

CRIS Chart

CRIS data by YCharts.

Overall, it's possible that fimepinostat could become a winner in time, but I'd much rather bet on a biotech with a history of winning than one that has destroyed so much value. For that reason, I'm content to look elsewhere for more promising opportunities.

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Curis, Inc. Stock Quote
Curis, Inc.
CRIS
$0.72 (2.86%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.